Secondary Prophylaxis Use of Romiplostim for the Prevention of Thrombocytopenia Induced by Temozolomide in Newly Diagnosed Glioblastoma Patients

Trial Profile

Secondary Prophylaxis Use of Romiplostim for the Prevention of Thrombocytopenia Induced by Temozolomide in Newly Diagnosed Glioblastoma Patients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 May 2017

At a glance

  • Drugs Romiplostim (Primary)
  • Indications Thrombocytopenia
  • Focus Therapeutic Use
  • Acronyms PLATUM
  • Most Recent Events

    • 17 May 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
    • 17 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
    • 13 Oct 2015 Planned primary completion date changed from 1 Jan 2017 to 1 Apr 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top